JP5577337B2 - 再灌流傷害を治療するための方法 - Google Patents

再灌流傷害を治療するための方法 Download PDF

Info

Publication number
JP5577337B2
JP5577337B2 JP2011521369A JP2011521369A JP5577337B2 JP 5577337 B2 JP5577337 B2 JP 5577337B2 JP 2011521369 A JP2011521369 A JP 2011521369A JP 2011521369 A JP2011521369 A JP 2011521369A JP 5577337 B2 JP5577337 B2 JP 5577337B2
Authority
JP
Japan
Prior art keywords
seq
hours
reperfusion
flagellin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011521369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529922A (ja
JP2011529922A5 (https=
Inventor
アンドレイ ブイ． グッドコフ，
ロバート フェアチャイルド，
Original Assignee
クリーブランド バイオラブス， インコーポレイテッド
クリーブランド クリニック ファウンデイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリーブランド バイオラブス， インコーポレイテッド, クリーブランド クリニック ファウンデイション filed Critical クリーブランド バイオラブス， インコーポレイテッド
Publication of JP2011529922A publication Critical patent/JP2011529922A/ja
Publication of JP2011529922A5 publication Critical patent/JP2011529922A5/ja
Application granted granted Critical
Publication of JP5577337B2 publication Critical patent/JP5577337B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2011521369A 2008-08-01 2009-07-31 再灌流傷害を治療するための方法 Expired - Fee Related JP5577337B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8576608P 2008-08-01 2008-08-01
US61/085,766 2008-08-01
PCT/US2009/052493 WO2010014957A1 (en) 2008-08-01 2009-07-31 Methods for treating reperfusion injuries

Publications (3)

Publication Number Publication Date
JP2011529922A JP2011529922A (ja) 2011-12-15
JP2011529922A5 JP2011529922A5 (https=) 2012-08-23
JP5577337B2 true JP5577337B2 (ja) 2014-08-20

Family

ID=41610763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011521369A Expired - Fee Related JP5577337B2 (ja) 2008-08-01 2009-07-31 再灌流傷害を治療するための方法

Country Status (10)

Country Link
US (4) US8324163B2 (https=)
EP (1) EP2320948B1 (https=)
JP (1) JP5577337B2 (https=)
CN (1) CN102170911B (https=)
AU (1) AU2009276357B2 (https=)
CA (1) CA2732763A1 (https=)
EA (1) EA020579B1 (https=)
ES (1) ES2412237T3 (https=)
PT (1) PT2320948E (https=)
WO (1) WO2010014957A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2460534A1 (en) 2004-12-22 2012-06-06 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
CN102170911B (zh) 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
WO2012097012A1 (en) 2011-01-10 2012-07-19 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US20150328284A1 (en) * 2012-04-02 2015-11-19 Cleveland Biolabs, Inc Compositions and methods comprising toll like receptor (tlr) stimulating agents for prophylaxis and therapy for damage to dermal epithelium
US10202426B2 (en) * 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
KR20240130829A (ko) 2016-08-11 2024-08-29 템플 유니버시티 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 허혈/재관류 손상
WO2019018768A1 (en) 2017-07-20 2019-01-24 Spogen Biotech Inc. BIOACTIVE POLYPEPTIDES FOR PLANT PROTECTION, GROWTH AND PRODUCTIVITY ENHANCEMENTS
US12440536B2 (en) * 2018-05-18 2025-10-14 The University Of Hong Kong Compositions of toll-like receptor 5 (TLR5) agonist and methods of use thereof
CN208752357U (zh) * 2018-09-21 2019-04-16 合肥京东方显示光源有限公司 背光模块及具有该背光模块的显示面板及显示器
KR102524577B1 (ko) 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
JPH05502402A (ja) 1990-09-28 1993-04-28 ゲブリユーダー　ズルツアー　アクチエンゲゼルシヤフト 医療用の中空針及びその製造方法
DE69333110T2 (de) 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
WO2001055210A2 (en) 2000-01-31 2001-08-02 Munin Corporation Human cyr61
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
WO2001040280A2 (en) 1999-11-29 2001-06-07 Inotek Corporation Composition and method for treating a microbial infection
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
WO2002044363A1 (en) 2000-11-28 2002-06-06 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP1379552B2 (en) 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-like receptor 5 ligands and methods of use
CA2462638A1 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
SG176524A1 (en) 2003-12-02 2011-12-29 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
US7638485B2 (en) * 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
EP1827489B1 (en) 2004-12-16 2012-10-31 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
EP2460534A1 (en) * 2004-12-22 2012-06-06 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
EP1940419A2 (en) * 2005-09-09 2008-07-09 Oregon Health and Science University Neuroprotectants
WO2007070623A2 (en) 2005-12-14 2007-06-21 Medistem Laboratories, Inc. Transcatheter tumor immunoembolization
EP2441846A3 (en) 2006-01-09 2012-07-25 The Regents Of the University of California Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy
EP2114427B1 (en) 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
RU2010107199A (ru) 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
CN101888856B (zh) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
WO2009102818A1 (en) 2008-02-11 2009-08-20 Cleveland Biolabs, Inc. Method for reducing the effects of chemotheraphy using flagellin related polypeptides
CN102170911B (zh) * 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
CA2777198C (en) 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer

Also Published As

Publication number Publication date
WO2010014957A1 (en) 2010-02-04
US20110135665A1 (en) 2011-06-09
JP2011529922A (ja) 2011-12-15
CA2732763A1 (en) 2010-02-04
US20130004515A1 (en) 2013-01-03
CN102170911B (zh) 2014-07-02
AU2009276357B2 (en) 2014-09-11
US20140220037A1 (en) 2014-08-07
US8324163B2 (en) 2012-12-04
CN102170911A (zh) 2011-08-31
EP2320948A1 (en) 2011-05-18
EA201170294A1 (ru) 2011-08-30
HK1161082A1 (en) 2012-08-24
US9006180B2 (en) 2015-04-14
US8618059B2 (en) 2013-12-31
EP2320948A4 (en) 2012-01-25
AU2009276357A1 (en) 2010-02-04
EA020579B1 (ru) 2014-12-30
EP2320948B1 (en) 2013-03-06
PT2320948E (pt) 2013-06-17
ES2412237T3 (es) 2013-07-10
US20150182587A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
JP5577337B2 (ja) 再灌流傷害を治療するための方法
Katare et al. Chronic intermittent fasting improves the survival following large myocardial ischemia by activation of BDNF/VEGF/PI3K signaling pathway
ES2714373T3 (es) Anticuerpo específico de endoglina para uso en un método de tratamiento de la insuficiencia cardíaca y de afecciones relacionadas
EP2544706B1 (en) Modulating aquaporins with relaxin
Cai et al. Up-regulation of Thioredoxin 1 by aerobic exercise training attenuates endoplasmic reticulum stress and cardiomyocyte apoptosis following myocardial infarction
US20080242615A1 (en) Surfactant protein-d for prevention and treatment of lung infections and sepsis
US7592310B2 (en) Induction of antibiotic proteins and peptides by LAIT/sCD14-protein
Topercerova et al. The effect of pulmonary surfactant on the airway smooth muscle after lipopolysaccharide exposure and its mechanisms.
CN118924752A (zh) Rip3抑制剂在制备减轻肺移植缺血再灌注损伤的药物组合物中的用途
Huang et al. Empagliflozin protects against pulmonary ischemia/reperfusion injury via an ERK1/2-dependent mechanism
HK1161082B (en) Methods for treating reperfusion injuries
US8895502B2 (en) β2-glycoprotein I peptide inhibitors
CN117100841A (zh) rLj-RGD3蛋白在绞窄性肠梗阻疾病方面的应用
KR20200139447A (ko) 항염증 조성물
Kim et al. Role of serotonin pathway in the mediation of postprandial pancreatic enzyme secretion in humans
MXPA00011511A (es) Inducción de proteinas y peptidos antibioticos por proteina lait/scd14

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140707

R150 Certificate of patent or registration of utility model

Ref document number: 5577337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees